Ewing sarcoma (ES) is a round cell sarcoma that can be challenging to diagnose on cytologic material given its significant overlap with numerous mesenchymal, epithelial, and lymphoid cytomorphologic mimics. The objective of this study was to assess the utility of a novel marker, NKX2.2, in the diagnosis of ES in cytologic material and its ability to distinguish ES from its mimics. METHODS: NKX2.2 immunohistochemistry was performed on cell blocks from 107 fine-needle aspirations, and nuclear expression was scored semiquantitatively for extent and intensity. The study cohort included ES (n = 10), well differentiated neuroendocrine tumor (n = 20), melanoma (n = 11), Merkel cell carcinoma (n = 10), small cell carcinoma (n = 10), alveolar rhabdomyosarcoma (n = 2), spindle cell/sclerosing rhabdomyosarcoma (n = 2), synovial sarcoma (n = 12), solitary fibrous tumor (n = 2), chronic lymphocytic leukemia (n = 10), lymphoblastic lymphoma (n = 11), adenoid cystic carcinoma (n = 6), and CIC-rearranged sarcoma (n = 1). RESULTS: NKX2.2 had high sensitivity (100%) and moderate specificity (85%) for the diagnosis of ES in cytologic material. NKX2.2 expression also was present in a subset of mesenchymal and epithelial mimics, and staining was most commonly observed in small cell carcinoma (80%) and well differentiated neuroendocrine tumor (45%). Among mesenchymal mimics, 42% exhibited NKX2.2 expression. NKX2.2 staining was absent in melanoma, adenoid cystic carcinoma, and lymphoproliferative neoplasms. CONCLUSIONS: NKX2.2 is a highly sensitive but only moderately specific marker for ES. Neuroendocrine neoplasms exhibit variable NKX2.2 expression and remain a significant potential diagnostic pitfall. Thus, NKX2.2 expression should be interpreted in the context of an appropriate immunohistochemical panel (and often with confirmatory molecular testing) for the accurate diagnosis of ES. Cancer Cytopathol 2018;126:942-949
INTRODUCTION
Ewing sarcoma (ES) is a prototypical "small round blue cell tumor" that commonly arises in the long bones of the lower extremities and pelvis of children and young adults (although 20% arise at extraosseous sites) and is often amenable to fine-needle aspiration (FNA) biopsy the given frequent cortical destruction and soft-tissue extension in ES. The use of optimized chemotherapy regimens that are specific for ES has increased the overall survival of patients with ES from 10% to 75% for localized disease, making the accurate diagnosis of ES of paramount importance. 1 In conjunction with cytomorphologic features, a diagnosis of ES can be supported by the identification of rearrangements involving the EWSR1 gene, most commonly with the FLI1
Cancer Cytopathology November 2018 fusion partner. [2] [3] [4] The characteristic fusion genes can be identified using reverse-transcription polymerase chain reaction or fluorescence in situ hybridization. 5 However, the identification of EWSR1 rearrangement alone is not specific for ES, because several other round cell sarcomas harbor such rearrangements; cytologic diagnosis may require expertise, which may not be widely available.
The differential diagnosis of small round blue cell neoplasms comprises a broad group of tumors composed of morphologically monotonous and poorly differentiated small round cells, and the distinction of ES from its mimics can be challenging on cytologic material. Definitive diagnosis often requires the use of ancillary testing, including immunohistochemical and molecular genetic studies. Currently, there is no single, highly sensitive and specific immunohistochemical marker for ES. Immunohistochemical markers FLI-1 and CD99 are currently used for the identification of ES; however, they have imperfect sensitivity and specificity and can be expressed in other small round cell tumors. [6] [7] [8] [9] NKX2.2 is a transcription factor that functions in neuronal and neuroendocrine differentiation and is both upregulated in ES and required for oncogenesis. 10, 11 Studies using material from resection specimens and surgical biopsies have indicated that NK2.2 is a highly sensitive and moderately specific immunohistochemical marker for ES, [12] [13] [14] [15] [16] [17] with increased specificity if used in combination with CD99. 13, 16 The aim of this study was to evaluate the diagnostic utility of NKX2.2 immunohistochemistry (IHC) in the distinction of ES from its cytomorphologic mimics on FNA material, including tumors of epithelial, mesenchymal, and lymphoid origin.
MATERIALS AND METHODS

Case Selection
Cases were selected retrospectively from the cytopathology and surgical pathology files of Brigham and Women's Hospital. FNA smears and hematoxylin and eosin (H&E)-stained cell block slides, as well as supporting IHC and molecular test results, were reviewed to confirm diagnosis and specimen adequacy. In total, 107 FNAs that had available cell blocks, including ES (n = 10), well differentiated neuroendocrine tumor (NET) (n = 20; 15 lung, 5 gastrointestinal), melanoma (n = 11),
Merkel cell carcinoma (n = 10), small cell carcinoma (n = 10), alveolar rhabdomyosarcoma (RMS) (n = 2), spindle cell/sclerosing RMS (n = 2), synovial sarcoma (n = 12), solitary fibrous tumor (SFT) (n = 2), chronic lymphocytic leukemia (CLL) (n = 10), lymphoblastic lymphoma (n = 11), adenoid cystic carcinoma (n = 6), and CIC-rearranged sarcoma (n = 1). Five ES cases had concurrent core biopsies, which also were reviewed.
Cell Block Preparation
Cell blocks were prepared using the plasma-thrombin method. FNA aspirates were washed in RPMI and centrifuged at 1800 revolutions per minute for 4 minutes. Aspirate cell pellets were mixed with equal parts plasma and thrombin to form a clotted pellet, which was then placed in a cassette and fixed in formalin for at least 4 hours. Fixed tissue was processed on the Peloris II Premium Tissue Processing System (Leica Biosystems, Wetzlar, Germany), on a 4-hour cycle. Cell block sections were cut at 4-μm intervals and stained with H&E using standard methods.
Immunohistochemistry
NKX2.2 IHC was performed on 4 μm-thick, formalinfixed, paraffin-embedded cytology cell blocks or whole tissue sections of biopsy cases after pressure cooker epitope retrieval (Target Retrieval Solution, pH 6.1; Dako, Carpinteria, CA) using a mouse anti-NKX2.2 monoclonal antibody (1:1000 dilution, 40-minute incubation, clone 74.5A5; Developmental Studies Hybridoma Bank, Iowa, IA). Appropriate positive controls (ES with confirmed EWSR1 rearrangement) and negative controls (normal colon, skeletal muscle, and skin) were used. NKX2.2 nuclear staining was assessed for each case and was scored semiquantitatively for extent (0; 1+, 1%-25%; 2+, 26%-75%; or 3+, >75%) and intensity (weak, moderate, or strong). Any extent of NKX2.2 expression was recorded; however, sensitivity, specificity, and positive predictive value were calculated using cases that had a staining extent score of at least 2+.
RESULTS
NKX2.2 Expression in ES
Nuclear NKX2.2 expression was present in all cases of ES (10 of 10 cases; 100%). All ES cases had either strong
Cancer Cytopathology November 2018 (7 of 10 cases; 70%) or moderate (3 of 10 cases; 30%) staining intensity, with either 3+ (8 of 10 cases; 80%) or 2+ (2 of 10 cases; 20%) staining extent ( Fig. 1 ). Five ES cases had concurrent core biopsies on which NKX2.2 IHC was performed, and NKX2.2 staining extent and intensity were concordant between all paired cell blocks and cores. NKX2.2 staining patterns in ES are summarized in Table 1 . All cases of ES exhibited diffuse, membranous CD99 staining (5 of 10 cases on cell block and the remaining cases on concurrent core biopsy (n = 4) and prior resection (n = 1). EWSR1 rearrangement was confirmed by fluorescence in situ hybridization in 7 of 10 cases during routine clinical evaluation.
NKX2.2 Expression in Other Mesenchymal Tumors
Overall, nuclear NKX2.2 was observed in 8 of 19 (42%) non-ES mesenchymal tumors. Nuclear NKX2.2 nuclear (Fig. 2) . Both SFT cases were negative for NKX2.2 (0 of 2 cases; 0%). Nuclear NKX2.2 staining was present in 1 of 2 cases (50%) of spindle cell/ sclerosing RMS, which exhibited weak staining intensity and 1+ staining extent. Both alveolar RMS cases were negative for NKX2.2 (0 of 2 cases; 0%). The CIC-rearranged sarcoma also was negative for NKX2.2 (0 of 1 cases; 0%).
NKX2.2 Expression in Nonmesenchymal Tumors
Among nonmesenchymal mimics, NKX2.2 positivity was present in 19 of 78 cases overall (24%). Nuclear NKX2.2 staining also was observed in 9 of 20 (45%) well differentiated NETs (Fig. 3A-F 
DISCUSSION
ES is a rare and aggressive tumor of predominantly pediatric patients and young adults that is characterized by balanced translocations involving EWSR1. 3 In approximately 90% of cases, the fusion partner of EWSR1 is FLI1, and most of the remaining cases involve fusions with the ERG. 18, 19 The demonstration of EWSR1 rearrangement has important diagnostic utility in the diagnosis of ES. However, numerous other mesenchymal tumors, including desmoplastic small round cell tumor, myxoid liposarcoma, clear cell sarcoma of soft tissue, as well as nonmesenchymal tumors such as clear cell carcinoma of the salivary gland, also harbor EWSR1 rearrangement. 20 Because the presence of EWSR1 rearrangement is not entirely specific for ES, immunohistochemical analysis of small round blue cell tumors is also an important component of the workup of small biopsies and allows for the triage of material for molecular studies when indicated. FLI1 IHC has been used for the diagnosis of ES; however, it has imperfect sensitivity and specificity. 6, 8 CD99
is the most commonly used immunohistochemical stain for the diagnosis of ES and is highly sensitive (particularly showing a diffuse, membranous pattern), but it is not entirely specific for ES. 7,9 NKX2.2 is a transcription factor that contains both activation and repressor domains and plays a role in neuronal differentiation, islet cell development in the pancreas, and endocrine cell development in the gastrointestinal tract. 10 Cancer Cytopathology November 2018 among tumors in this group, but there is also overlap in the expression of immunohistochemical markers. ES and its morphologic mimics can display variable staining of both neuroendocrine markers and keratins in addition to NKX2.2. Because of the known roles of NKX2.2 in neuronal and endocrine development, positive staining can be observed in various tumor types with various degrees of intensity and extent. In the current study, we demonstrate high sensitivity (100%) of NKX2.2 in the diagnosis of ES on cytologic material; however, its specificity is moderate (84%). These findings are comparable to the previously reported sensitivity (range, 80%-93%) and specificity (range, 84%-89%) of NKX2.2 for the diagnosis of ES in surgical specimens. [14] [15] [16] Notably, the presence of NKX2.2 positivity in tumors other than ES in our current study reflects the varied, known biologic roles of NKX2.2 described above. We observed that NKX2.2 expression was more common in epithelial tumors of neuroendocrine differentiation, including small cell carcinoma, Merkel cell carcinoma, and well differentiated NET, and the positive predictive value of NKX2.2 for ES in this context was 0.34. Within the well-differentiated NET group, there was further delineation of NKX2.2 staining based on anatomic site of origin, with positivity observed in all gastrointestinal well differentiated NETs (5 of 5 cases) but only in a subset of pulmonary NETs (4 of 15 cases). This finding is consistent with prior studies demonstrating the presence of NKX2.2 positivity in well differentiated NETs of gastrointestinal origin versus those of pulmonary origin, which is in keeping with the demonstrated role of NKX2.2 in gastrointestinal tract endocrine cell differentiation. 24, 25 In addition to the expression of NKX2.2 in tumors with neuroendocrine differentiation, studies have shown that ES can express neuroendocrine markers, and the cytomorphologic and immunohistochemical overlap poses diagnostic pitfalls. ES occasionally may be misdiagnosed as NET in the lung; one such example reported from our institution was a pulmonary mass initially diagnosed as atypical carcinoid tumor; however, routine next-generation sequencing subsequently detected EWSR1-ERG fusion. 26 In the scenario of a round cell neoplasm in the lung, NET remains a diagnostic pitfall for ES given the overlapping immunohistochemical features between entities. NKX2.2 expression has more limited discriminatory capability in this context and should be supplemented by a panel that includes CD99 to prompt confirmatory molecular testing.
Although ES is not of epithelial origin, it can aberrantly express keratins in up to 30% of cases, and staining can range from focal to diffuse. 27, 28 Indeed, the so-called adamantinoma-like ES variant can display overt keratinization and is positive for keratins and p40. 13 Keratin positivity is important to consider in small FNA biopsy specimens, especially in the context of described positivity of neuroendocrine markers in ES. In combination with neuroendocrine marker positivity, keratin expression is a potential pitfall for which NKX2.2 can be useful in many scenarios to distinguish between neuroendocrine carcinomas and ES. However, the potential overlap of NKX2.2, neuroendocrine markers, and keratin staining between ES and well differentiated neuroendocrine tumors (notably those of gastrointestinal origin) requires careful correlation with clinical context. In these cases, the broader extent and stronger staining of NKX2.2 in ES may be helpful for distinguishing ES from these cytomorphologic mimics; however, challenging cases may require molecular testing to confirm the presence of EWSR1 rearrangement. There are several mesenchymal neoplasms that demonstrate morphologic overlap with ES; and, in our current study, we observed that NKX2.2 positivity was most frequent in synovial sarcoma (58%; 7 of 12 cases). For example, poorly differentiated synovial sarcomas can exhibit round cell morphology. In a prior study, Rooper et al reported absent NKX2.2 expression in the majority of synovial sarcomas; however, they observed rare cases with focal NKX2.2 staining, which comprised <5% of tumor cells (but did not reach their threshold for a "positive" result).
12 TLE-1 is a sensitive but more modestly specific marker for synovial sarcoma and is consistently negative in ES. 29, 30 14 Certain lymphoproliferative disorders also may enter the differential diagnosis of ES, and lymphoblastic lymphoma in particular poses a cytomorphologic diagnostic pitfall. Lymphoblastic lymphoma is an aggressive lymphoproliferative disorder identified in a similar demographic group as ES and may arise as a primary bone or soft tissue tumor. 31 Lymphoblastic lymphoma often has variable or negative staining for conventional lymphoma markers, is often positive for terminal deoxynucleotidyl transferase, and can be positive for CD99 and FLI1. 32 We observed that NKX2.2 was negative in 100%
of lymphoblastic lymphoma cases. Therefore, an immunohistochemical panel that includes both NKX2.2 and terminal deoxynucleotidyl transferase would be useful to exclude lymphoblastic lymphoma, given that both entities can express CD99. Previous work assessing surgical specimens has demonstrated that the combination of CD99 and NKX2.2 is more specific than either alone for the identification of ES, with a combined specificity of 98%, although a lower sensitivity of 80% was reported for the combination. 16 On the basis of our current findings, the inclusion of NKX2.2 IHC for the initial workup of suspected ES on cytologic material has high diagnostic utility, and NKX2.2 should be included in combination with a panel of CD99 and additional epithelial, neuroendocrine, and mesenchymal markers, as appropriate. Consideration of the overlapping cytomorphologic and immunohistochemical profiles of ES with its morphologic mimics, the use of appropriate immunohistochemical panels to direct confirmatory molecular testing, and integration with clinical and radiology findings are crucial for the accurate diagnosis of ES and appropriate patient management.
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